Surprisingly, blocking c-Src activation through dasatinib was able to inhibit the EGFR survival signaling by sealing tyrosine 1068, 1086, and 1145 of EGFR, which in turn increased the antitumor activity of TKIs in EGFR-mutant lung adenocarcinoma. Here, SRC is linked to lung adenocarcinoma.